The 340B Drug Pricing Program at a Crossroads
JAMA · 16.06.2026 · 335 (23) · 2009
DOI: 10.1001/jama.2026.6812 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 16.06.2026. Verfasst von Ryan P Knox und 1 weiteren Autor:innen. Beteiligte Einrichtung: DePaul University College of Law, Chicago, Illinois. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint presents the history of the Health Resources & Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limitations, and calls for action by Congress and HRSA to address these issues and strengthen support for safety-net hospitals and clinics.
Autor:innen und Institutionen
- DePaul University College of Law, Chicago, Illinois.
- Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Knox, R. P., & Sarpatwari, A. (2026). The 340B Drug Pricing Program at a Crossroads. JAMA, 335(23), 2009. https://doi.org/10.1001/jama.2026.6812
Vancouver
Knox RP, Sarpatwari A. The 340B Drug Pricing Program at a Crossroads. JAMA. 2026;335(23):2009. doi:10.1001/jama.2026.6812
BibTeX
@article{Knox2026,
author = {Knox, Ryan P and Sarpatwari, Ameet},
title = {The 340B Drug Pricing Program at a Crossroads},
journal = {JAMA},
year = {2026},
volume = {335},
number = {23},
pages = {2009},
doi = {10.1001/jama.2026.6812}
}
EUVIMED